Severity
Moderate
FDA Drug recall · Reported March 9, 2016
Failed Dissolution Specifications: low test results at the 18 month time-point
Teva North America recalled Capecitabine tablets USP 500 mg, Cytotoxic Agent, Rx Only, 120 tablets per bottle, Manufa… - a moderate-severity action.
Capecitabine tablets USP 500 mg, Cytotoxic Agent, Rx Only, 120 tablets per bottle, Manufa… was recalled by Teva North America in March 9, 2016. Reason: Failed Dissolution Specifications: low test results at the 18 month time-point. Check the official notice for the remedy. Verify recall #D-0732-2016 with the FDA Drug before acting.
The recall
Teva North America issued this moderate-severity FDA Drug recall-Failed Dissolution Specifications: low test results at the 18 month time-point.
Sourced from official FDA Drug enforcement records. Verify recall #D-0732-2016 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0732-2016) was formally reported on March 9, 2016, with the manufacturer initiating the action on December 21, 2015. It is classified under Moderate severity (Class II), with a current status of Terminated. Teva North America is listed as the recalling firm, operating out of Horsham, PA. Federal records list the affected scope as 1,895 bottles.
The documented reason for this recall is: Failed Dissolution Specifications: low test results at the 18 month time-point Distribution data in the federal record shows the product reached: Nationwide. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 3,731 children & baby products recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
1,895 bottles
Related Recalls
6
0 from same agency
Capecitabine tablets USP 500 mg, Cytotoxic Agent, Rx Only, 120 tablets per bottle, Manufactured in Czech Republic by: Teva Czech Industries sro, Czech Republic, Manufactured for: Teva Pharmaceuticals USA, Sellersville, PA 18960, NDC 0093-7474-89
Failed Dissolution Specifications: low test results at the 18 month time-point
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Terminated |
| Recall number | D-0732-2016 |
| Date reported | March 9, 2016 |
| Date initiated | December 21, 2015 |
| Recalling firm | Teva North America |
| Firm location | Horsham, PA |
| Affected scope | 1,895 bottles |
| Distribution | Nationwide |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
Xishentang Dongguan Trading Co, Ltd., dba Pretty-Life, of China · 2026-07-02
Diamond Wipes International, Inc. of Chino, California · 2026-07-02
· 2026-07-02
· 2026-07-02
Sanven Technology Ltd., dba Vevor, of Rancho Cucamonga, California · 2026-07-02
Compare this recall with AMASKY Nursing Pillows Recalled Due to Risk of Serious Inju… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported March 9, 2016. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.